Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir

References

• World Health Organization. The World Health Report 2003:shaping the future. Geneva: World Health Organization, 2003. http://www.who.int/whr/2003/en/whr03_en.pdf.2003.
   Google Scholar
• Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529–38.
   PubMed Web of Science ®Google Scholar
• Janssen HL, van ZM, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, . Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123–9.
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682–95.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–42.
   PubMed Web of Science ®Google Scholar
• Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002–9.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206–17.
   PubMed Web of Science ®Google Scholar
• Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699–705.
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798–801.
   PubMed Web of Science ®Google Scholar
• Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010;202:1749–53.
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Polymorphisms near IL28B and serological response to peginterferon in HBeAg-Positive patients with chronic hepatitis B. Gastroenterology 2011. [Epub ahead of print]
   PubMedGoogle Scholar
• Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 2011;31:1118–26.
   PubMedGoogle Scholar
• Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63–8.
   PubMed Web of Science ®Google Scholar
• Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008;105:7034–9.
   PubMed Web of Science ®Google Scholar
• Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010;139:499–509.
   PubMed Web of Science ®Google Scholar
• Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010;52:1888–96.
   PubMed Web of Science ®Google Scholar
• Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101:6669–74.
   PubMed Web of Science ®Google Scholar
• Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004;78:13779–92.
   PubMed Web of Science ®Google Scholar
• Lutgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann JH, Pollok JM, Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 2011;140:2074–83; 2083.
   PubMedGoogle Scholar
• Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci 2010;55:2727–34.
   PubMed Web of Science ®Google Scholar
• Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215–29.
   PubMed Web of Science ®Google Scholar
• Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009;113:5868–77.
   PubMed Web of Science ®Google Scholar